Immunophenotypic analysis of erythroid dysplasia and its diagnostic application in myelodysplastic syndromes

Internal Medicine Journal

Volumn 42, Issue 4, 2012, Pages 401-411

  Xu, F ^a,b   Wu, L ^a   He, Q ^a   Zhang, Z ^a   Chang, C ^a   Li, X ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CD105; CD71; Diagnosis; Immunophenotype; Myelodysplastic syndrome

Indexed keywords

CD71 ANTIGEN; ENDOGLIN; HEMOGLOBIN; HLA DR15 ANTIGEN;

ADULT; AGED; ARTICLE; BONE MARROW DISEASE; CANCER PATIENT; CHROMOSOME ANALYSIS; CONTROLLED STUDY; CYTOPENIA; DIAGNOSTIC TEST; ERYTHROBLAST; ERYTHROCYTE TRANSFUSION; ERYTHROID DYSPLASIA; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CYTOGENETIC ANALYSIS; DIAGNOSIS, DIFFERENTIAL; ERYTHROBLASTS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECEPTORS, CELL SURFACE; RECEPTORS, TRANSFERRIN; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84859813890     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02630.x     Document Type: Article

References (32)

1. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007; 7: 118-29.
2. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P etal. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007; 31: 727-36.
3. Xu F, Li X, Wu L, He Q, Zhang Z, Chang C etal. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes. Br J Haematol 2010; 149: 587-97.
4. Lorand-Metze I, Ribeiro E, Lima CS, Batista LS, Metze K. Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders. Leuk Res 2007; 31: 147-55.
5. Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ etal. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001; 98: 979-87.
6. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM etal. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003; 102: 394-403.
7. Benesch M, Deeg HJ, Wells D, Loken M. Flow cytometry for diagnosis and assessment of prognosis in patients with myelodysplastic syndromes. Hematology 2004; 9: 171-7.
8. Stachurski D, Smith BR, Pozdnyakova O, Andersen M, Xiao Z, Raza A etal. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res 2008; 32: 215-24.
9. Ogata K, Kishikawa Y, Satoh C, Tamura H, Dan K, Hayashi A etal. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 2006; 108: 1037-44.
10. Cherian S, Moore J, Bantly A, Vergilio JA, Klein P, Luger S etal. Peripheral blood MDS score: a ne w flow cytometric tool for the diagnosis of myelodysplastic syndromes. Cytometry B Clin Cytom 2005; 64: 9-17.
11. Ogata K, Nakamura K, Yokose N, Tamura H, Tachibana M, Taniguchi O etal. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002; 100: 3887-96.
12. Font P, Subirá D, Mtnez-Chamorro C, Castañón S, Arranz E, Ramiro S etal. Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome. Leuk Res 2006; 30: 957-63.
13. van de Loosdrecht AA, Westers TM, Westra AH, Dräger AM, van der Velden VH, Ossenkoppele GJ. Identification of distinct prognostic subgroups in low- and intermediate-1 risk myelodysplastic syndromes by flow cytometry. Blood 2008; 111: 1067-77.
14. Della Porta MG, Malcovati L, Invernizzi R, Travaglino E, Pascutto C, Maffioli M etal. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Blood 2004; 20: 549-55.
15. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G etal. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-88.
16. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-302.
17. Gonzalez-Garcia JR, Meza-Espinoza JP. Use of the International System for Human Cytogene- tic Nomenclature (ISCN). Blood 2006; 108: 3952-3.
18. Li X, Liao Q, Zhang Y, Zhang Z, Song LX, Xu L etal. Experimental and clinical characteristics in myelodysplastic syndrome patients with or without HLA-DR15 allele. Hematol Oncol 2010; 28: 98-103.
19. Malcovati L, Della Porta MG, Lunghi M, Pascutto C, Vanelli L, Travaglino E etal. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia 2005; 19: 776-83.
20. Metzgeroth G, La Rosée P, Kuhn C, Schultheis B, Dorn-Beineke A, Hehlmann R etal. The soluble transferrin receptor in dysplastic erythropoiesis in myelodysplastic syndrome. Eur J Haematol 2006; 79: 8-16.
21. Okumura N, Tsuji K, Nakahata T. Changes in cell surface antigen expression during proliferation and differentiation of human erythroid progenitors. Blood 1992; 80: 642-50.
22. Serke S, Huhn D. Identification of CD71 (transferrin receptor) expressing erythrocytes by multiparameter-flow-cytometry (MP-FCM): correlation to the quantitation of reticulocytes as determined by conventional microscopy and byMP-FCMusing a RNA-staining dye. Br J Haematol 1992; 81: 432-9.
23. Matsuda A, Bessho M, Mori S, Takeuchi T, Abe T, Yawata Y etal. Diagnostic significance of serum soluble transferrin receptors in various anemic diseases: the first multi-institutional joint study in Japan. Haematologia (Budap) 2002; 32: 225-38.
24. Bowen DT, Culligan D, Beguin Y, Kendall R, Willis N. Estimation of effective and total erythropoiesis in myelodysplasia using serum transferrin receptor and erythropoietin concentrations, with automated reticulocyte parameters. Leukemia 1994; 8: 151-5.
25. Kuiper-Kramer PA, Huisman CM, Van der Molen-Sinke J, Abbes A, Van Eijk HG. The expression of transferrin receptors on erythroblasts in anaemia of chronic disease, myelodysplastic syndromes and iron deficiency. Acta Haematol 1997; 97: 127-31.
26. van Lochem EG, van der Velden VH, Wind HK, te Marvelde JG, Westerdaal NA, van Dongen JJ. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry Part B 2004; 60: 1-13.
27. Rokhlin OW, Cohen MB, Kubagawa H, Letarte M, Cooper MD. Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. J Immunol 1995; 154: 4456-65.
28. Bühring HJ, Müller CA, Letarte M, Gougos A, Saalmüller A, van Agthoven AJ etal. Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. Leukemia 1991; 5: 841-7.
29. Lammers R, Giesert C, Grünebach F, Marxer A, Vogel W, Bühring HJ. Monoclonal antibody 9C4 recognizes epithelial cellular adhesion molecule, a cell surface antigen expressed in early steps of erythropoiesis. Exp Hematol 2002; 30: 537-45.
30. Saunthararajah Y, Nakamura R, Nam JM, Robyn J, Loberiza F, Maciejewski JP etal. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002; 100: 1570-74.
31. Biesma DH, Van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer 2000; 79: 1548-51.
32. Nand S, Godwin JE. Hypoplastic myelodysplastic syndrome. Cancer 2006; 62: 958-64.